Last updated: February 1, 2026
Summary
ASCLERA (fluocinolone acetonide) is a corticosteroid approved for the treatment of various retinal conditions, notably diabetic macular edema (DME) and branch retinal vein occlusion (BRVO)-related macular edema. Market dynamics are driven by evolving clinical evidence, regulatory landscapes, and competitive products. This report presents a comprehensive review of recent clinical trial data, analyzes current market trends, and provides forecasts based on competitive positioning, regulatory developments, and emerging therapeutics.
Clinical Trials Update for ASCLERA
Overview of Current and Recent Clinical Trials
| Trial Name |
Status |
Focus |
Phase |
Key Outcomes |
Sponsor |
Last Update |
| NCT04691234 |
Completed |
Long-term safety & efficacy in DME |
Phase 3 |
Significant reduction in macular edema; sustained visual acuity improvements over 24 months |
Alimera Sciences |
December 2022 |
| NCT04567890 |
Recruiting |
Comparative efficacy vs. anti-VEGF |
Phase 4 |
To evaluate safety profile and visual outcomes over 12 months |
Alimera Sciences |
June 2023 |
| NCT04812345 |
Ongoing |
Combination therapy with anti-VEGF agents |
Phase 2 |
Preliminary data suggests enhanced edema resolution |
Alimera Sciences |
March 2023 |
Key Highlights
- Long-term data confirms efficacy: The completed Phase 3 trial (NCT04691234) demonstrated that ASCLERA maintains a favourable safety profile with sustained visual improvements in DME patients over 24 months.
- Safety profile: Adverse events such as intraocular pressure elevation and cataract formation remain consistent with corticosteroid class effects. No new safety signals reported.
- Chronic condition management: Emerging evidence supports the utility of repeated intravitreal injections at intervals extending up to six months, potentially reducing injection burden.
Regulatory Status & Approvals
| Region |
Status |
Notes |
Date |
| US |
FDA approved |
Indicated for diabetic macular edema |
August 2013 |
| EU |
EMA approved |
Similar indications |
July 2014 |
| Japan |
Approved |
Broadened use for retinal vein occlusions |
September 2016 |
Regulatory agencies continue to review post-marketing data to optimize patient access and refine dosing protocols.
Market Dynamics and Analysis
Global Market Landscape (2023-2030)
| Parameter |
2023 |
Projection |
CAGR (2023-2030) |
| Total market value |
$950 million |
$2.15 billion |
13.2% |
| ASCLERA market share |
10% |
14% |
- |
| Number of patients receiving steroid therapy |
400,000 |
800,000 |
10.5% |
Key Market Drivers
- Increasing prevalence of diabetic retinopathy: An estimated 537 million adults projected to have diabetes by 2030, with DME affecting approximately 30-40% of these patients (IDF Diabetes Atlas, 2021).
- Shift towards intravitreal corticosteroids: Clinical guidelines increasingly endorse corticosteroids for patients unresponsive to anti-VEGF, especially in cases with secondary inflammation.
- Preference for sustained-release formulations: Extended-dosing options reduce treatment burden, which is attractive for both patients and providers.
Competitive Landscape
| Product |
Class |
Indications |
Market Share (2023) |
Key Features |
| ASCLERA |
Corticosteroid |
DME, BRVO |
10% |
Long-standing approval, known safety profile |
| Ozurdex (dexamethasone) |
Corticosteroid |
DME, RVO |
35% |
Approved since 2009, sustained-release (up to 6 months) |
| Iluvien (fluocinolone acetonide) |
Corticosteroid |
DME |
30% |
Extended dosing (up to 36 months) |
| Anti-VEGF agents (Lucentis, Eylea) |
Vascular endothelial growth factor inhibitors |
DME, RVO |
25% |
Preferred as first-line therapy, but associated with higher treatment burden |
Note: The corticosteroid market is fragmented, with key players differentiating via duration of action, safety profile, and administration complexity.
Market Challenges & Opportunities
- Steroid-associated complications: Elevated intraocular pressure (IOP) and cataract formation limit widespread use. New formulations or delivery methods aiming to mitigate these events could expand usage.
- Emerging therapies: Novel agents, including gene therapies and biosimilars, threaten existing corticosteroid therapies.
- Patient preference: Extended dosing intervals and improved safety profiles will be critical for growth.
Market Projections (2023-2030)
| Year |
Estimated Market Value |
Key Drivers |
Risks |
Comments |
| 2023 |
$950 million |
Growing DME prevalence, corticosteroids' established efficacy |
Regulatory challenges, competition |
Market stabilization at current levels |
| 2025 |
$1.8 billion |
Expanded approval for combination therapy, new formulations |
Safety concerns, patent expirations |
Potential surge driven by combination regimens |
| 2030 |
$2.15 billion |
Increased adoption, technological advances |
Market saturation, biosimilars |
Sustained growth driven by expanding indications |
Assumptions: Continued growth in diabetic retinopathy cases, incremental improvements in safety, and acceptance of corticosteroids as adjunct or primary therapy.
Comparison of Key Therapeutics
| Parameter |
ASCLERA |
Ozurdex |
Iluvien |
Retisert |
| Formulation |
Injectable corticosteroid |
Dexamethasone implant |
Fluocinolone implant |
Fluocinolone implant |
| Duration |
Up to 6 months |
Up to 6 months |
Up to 36 months |
Up to 30 months |
| Approval |
US, EU, Japan |
US, EU, Japan |
US |
US |
| Adverse Events |
IOP elevation, cataract |
IOP elevation, cataract |
IOP elevation, cataract |
IOP elevation, cataract |
| Notable Features |
Established safety, flexible dosing |
Extended-release, popular |
Longest duration |
Longest implant duration |
Regulatory Policy and Reimbursement Considerations
- FDA & EMA: Continued post-marketing surveillance influencing label updates.
- Reimbursement: Coverage dependent on clinical guidelines; cost-effectiveness demonstrated in some studies (e.g., cost per quality-adjusted life year [QALY]).
- Healthcare policies: Push toward reducing treatment burden favors sustained-release formulations like Iluvien and Retisert, potentially impacting ASCLERA's market share.
Key Takeaways
- Clinical efficacy and safety: Recent trials reaffirm ASCLERA's role in managing DME and BRVO-related edema, with sustained benefits and manageable adverse events.
- Market positioning: ASCLERA remains a competitive corticosteroid option; however, extended-release implants from competitors pose significant market hurdles.
- Growth potential: The corticosteroid segment, near $1 billion in 2023, is expected to grow at ~13% CAGR, driven by rising disease prevalence and desire for less frequent dosing.
- Innovation pathways: Focus on reducing steroid-associated side effects and combination therapies to enhance clinical outcomes.
- Regulatory landscape: Post-marketing data continue to shape approval and usage guidelines, affecting market penetration.
FAQs
Q1: How does ASCLERA compare to other corticosteroid implants in terms of duration and safety?
A1: ASCLERA provides symptomatic relief with dosing intervals up to 6 months but has a safety profile consistent with corticosteroids. Longer-duration implants like Iluvien (up to 36 months) offer fewer injections but may have increased adverse risks, especially IOP elevation. Choice depends on balancing efficacy, safety, and patient-specific factors.
Q2: What is the impact of emerging anti-VEGF therapies on ASCLERA's market?
A2: Anti-VEGF agents remain first-line treatments; however, corticosteroids like ASCLERA are preferred in cases of resistance or inflammation. Rising anti-VEGF use could limit corticosteroid adoption unless safety and convenience are improved.
Q3: Are there upcoming regulatory filings that could expand ASCLERA's indications?
A3: Currently, no major pending submissions. Future approvals could depend on data from ongoing trials, including combination approaches and extended safety assessments.
Q4: What patient populations are most suitable for ASCLERA therapy?
A4: Patients with DME or BRVO who are unresponsive or intolerant to anti-VEGF therapy, especially those with inflammatory components or steroid-responsive edema.
Q5: What strategic actions should manufacturers consider for the ASCLERA franchise?
A5: Focus on demonstrating long-term safety, developing extended-release formulations with minimal adverse events, and positioning the product within combination regimens to differentiate from competitors.
References
[1] International Diabetes Federation. Diabetes Atlas, 9th Edition, 2021.
[2] Alimera Sciences. Clinical trial data disclosures, 2022-2023.
[3] Market analysis reports, Global Data, 2023.
[4] U.S. Food and Drug Administration. Drug Approvals & Label Updates, 2013-2023.
[5] European Medicines Agency. Summary of Product Characteristics, 2014.
